Anti-Inflammatory drug could boost stroke recovery after clot removal
NCT ID NCT07449910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the anti-inflammatory drug baricitinib to standard clot-removal treatment helps people recover better after a severe stroke caused by a blocked artery in the front of the brain. About 750 adults will receive either baricitinib or a placebo for five days, and their level of disability will be measured three months later. The goal is to see if calming brain inflammation can reduce long-term disability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Baricitinib (an anti-inflammatory drug)
- What this could lead to
- If it works, this could offer a new way to improve recovery and reduce disability after a major stroke by adding an anti-inflammatory drug to standard clot-removal treatment.
- What could go wrong
- This is an early-to-mid-stage trial (Phase 2/3) with 750 participants. The drug may not improve outcomes, and there are risks of infection or other side effects from baricitinib.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ANTERIOR CIRCULATION LARGE VESSEL OCCLUSION STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Recruiting
Hefei, Anhui, 230001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.